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BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a common comorbidity in heart failure with reduced ejection 
fraction, associated with undertreatment and worse outcomes. New treatments for heart failure with reduced ejection fraction 
may be particularly important in patients with concomitant COPD.
METHODS AND RESULTS: We examined outcomes in 8399 patients with heart failure with reduced ejection fraction, according to COPD 
status, in the PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Blocker–Neprilysin Inhibitor With Angiotensin-
Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial. Cox regression models were 
used to compare COPD versus non-COPD subgroups and the effects of sacubitril/valsartan versus enalapril. Patients with COPD 
(n=1080, 12.9%) were older than patients without COPD (mean 67 versus 63 years; P<0.001), with similar left ventricular ejection frac-
tion (29.9% versus 29.4%), but higher NT-proBNP (N-terminal pro-B-type natriuretic peptide; median, 1741 pg/mL versus 1591 pg/
mL; P=0.01), worse functional class (New York Heart Association III/IV 37% versus 23%; P<0.001) and Kansas City Cardiomyopathy 
Questionnaire–Clinical Summary Score (73 versus 81; P<0.001), and more congestion and comorbidity. Medical therapy was similar 
in patients with and without COPD except for beta-blockade (87% versus 94%; P<0.001) and diuretics (85% versus 80%; P<0.001). 
After multivariable adjustment, COPD was associated with higher risks of heart failure hospitalization (hazard ratio [HR], 1.32; 95% CI, 
1.13–1.54), and the composite of cardiovascular death or heart failure hospitalization (HR, 1.18; 95% CI, 1.05–1.34), but not cardio-
vascular death (HR, 1.10; 95% CI, 0.94–1.30), or all-cause mortality (HR, 1.14; 95% CI, 0.99–1.31). COPD was also associated with 
higher risk of all cardiovascular hospitalization (HR, 1.17; 95% CI, 1.05–1.31) and noncardiovascular hospitalization (HR, 1.45; 95% 
CI, 1.29–1.64). The benefit of sacubitril/valsartan over enalapril was consistent in patients with and without COPD for all end points.
CONCLUSIONS: In PARADIGM-HF, COPD was associated with lower use of beta-blockers and worse health status and was 
an independent predictor of cardiovascular and noncardiovascular hospitalization. Sacubitril/valsartan was beneficial in this 
high-risk subgroup.
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The quest to improve outcomes for patients with heart failure (HF) has recently focused not only on the underlying disease but also on the asso-
ciated comorbidities. Chronic obstructive pulmonary 
disease (COPD) is increasing in prevalence, has few 
effective therapies, and is predicted to be the third 
leading cause of death worldwide by 2030.1 Up to 
one-third of unselected patients with stable HF have 
concurrent COPD, largely because of the shared risk 
factor of smoking.2 Cumulative smoking exposure 
has been associated with incident HF and ventric-
ular remodeling, but the effect of COPD as an in-
dependent contributor to HF outcomes is less well 
understood.3–7
One potential contributor to the higher rates of 
death and hospitalization in patients with HF with 
reduced ejection fraction (HFrEF) who have COPD, 
compared with patients with HFrEF who do not have 
COPD, is underuse of beta-blockers because of per-
ceived or actual intolerance of these drugs in people 
with COPD. This highlights the importance of alterna-
tive therapies in these particularly high-risk patients 
with the combination of HFrEF and COPD. A recent 
therapeutic advance in HFrEF has been the intro-
duction of neprilysin inhibition (used in conjunction 
with an angiotensin receptor blocker). However, the 
potential effects of neprilysin inhibition in HFrEF pa-
tients with COPD, especially those with concomitant 
pulmonary hypertension, is uncertain, with conflict-
ing experimental and other data. Mice genetically de-
ficient in neprilysin develop exaggerated pulmonary 
vascular remodeling in response to chronic hypoxia 
and in another study, lung tissue from patients with 
severe COPD showed reduced neprilysin activity 
and protein expression, and more pulmonary vas-
cular remodeling.8,9 These observations gave rise to 
a hypothesis that decreased neprilysin activity con-
tributes to the adverse pulmonary vascular remodel-
ing in COPD. On the other hand, neprilysin inhibition 
has been shown to acutely reduce pulmonary artery 
pressure in patients with pulmonary hypertension 
and there are recent reports that sacubitril/valsartan 
reduces pulmonary artery pressure and improves 
right ventricular function in experimental models and 
case series.10–14 The PARADIGM-HF (Prospective 
Comparison of Angiotensin Receptor Blocker–
Neprilysin Inhibitor With Angiotensin-Converting 
Enzyme to Determine Impact on Global Mortality and 
Morbidity in Heart Failure) trial provides a large, con-
temporary cohort to further characterize the inter-
action between HF and COPD, assess the effect of 
sacubitril/valsartan in patients with COPD, and iden-
tify areas for improvement in management of these 2 
important diseases.15,16
METHODS
PARADIGM-HF was a randomized, double blind trial 
comparing the long-term efficacy and safety of enal-
april and sacubitril/valsartan in patients with chronic 
symptomatic HF and reduced left ventricular ejection 
fraction (LVEF). The study design and primary results 
have been described previously.15–17 The trial was ap-
proved by the ethics committee at each study center, 
and all patients provided written informed consent. 
The data that support the findings of this study are 
CLINICAL PERSPECTIVE
What Is New?
• Patients with chronic obstructive pulmonary dis-
ease (COPD) had a higher risk of cardiovascular 
(including heart failure) and noncardiovascular 
hospitalization than patients without COPD.
• COPD was associated with a lower (worse) 
baseline Kansas City Cardiomyopathy Ques-
tionnaire–Clinical Summary Score, and at 
8 months, patients with COPD were more likely 
to experience a clinically important deterioration 
in Kansas City Cardiomyopathy Questionnaire–
Clinical Summary Score than patients without 
COPD.
• Overall, the uptake of influenza vaccination was 
low, which is a major cause for concern.
What Are the Clinical Implications?
• As the benefit of sacubitril/valsartan over enal-
april was consistent in patients with and without 
COPD for all end points, patients with COPD 
obtained a large absolute benefit from angio-
tensin receptor–neprilysin inhibition because of 
their high baseline risk.
• The low rates of influenza vaccination and 
high prevalence of continuing smoking in pa-
tients with heart failure and COPD represent 
targets for public health initiatives and quality 
improvement.
Nonstandard Abbreviations and Acronyms
HFrEF  heart failure with reduced ejection 
fraction
IRR incidence rate ratio
KCCQ  Kansas City Cardiomyopathy 
Questionnaire






 http://ahajournals.org by on A
pril 20, 2021
J Am Heart Assoc. 2021;10:e019238. DOI: 10.1161/JAHA.120.019238 3
Ehteshami-Afshar et al Impact of COPD in Patients With HFrEF
available from the corresponding author upon reason-
able request.
Study Design and Population
The trial enrolled patients with New York Heart 
Association class II–IV symptoms, LVEF ≤40% 
(amended to ≤35% during study), and plasma BNP 
(B-type natriuretic peptide) ≥150 pg/mL or NT-proBNP 
(N-terminal pro-B-type natriuretic peptide) ≥600  pg/
mL. Patients hospitalized for HF within the preceding 
12 months were enrolled with a lower natriuretic pep-
tide concentration (BNP ≥100  pg/mL or NTpro-BNP 
≥400  pg/mL). Patients tolerating enalapril and sacu-
bitril/valsartan at target doses during a run-in period 
were randomly assigned to double-blind treatment 
with either enalapril 10 mg twice daily or sacubitril/vals-
artan 97/103 mg twice daily. Participants were followed 
for a median duration of 27 months. Exclusion criteria 
included symptomatic hypotension, estimated glo-
merular filtration rate <30 mL/min per 1.73 m2; serum 
potassium concentration >5.2  mmol/L at screening; 
history of angioedema; and recent acute coronary syn-
drome, cardiovascular procedure, or surgery.
COPD or asthma was not an exclusion criterion. 
The presence of COPD was recorded using a yes/
no check box by individual site investigators at study 
entry. Two particular aspects of the COPD history were 
uniquely recorded in PARADIGM-HF compared with 
other contemporary clinical trials: smoking history and 
vaccination record.
Study End Points
The primary outcome was the composite of cardiovas-
cular death or first hospitalization for HF. Secondary 
outcomes were cardiovascular death, HF hospitaliza-
tion, and all-cause mortality. We analyzed the primary 
outcome, heart failure hospitalization, and deaths (all-
cause, noncardiovascular and cardiovascular, with 
cardiovascular further subclassified as sudden or at-
tributable to worsening heart failure). In PARADIGM-HF, 
deaths that could be classified were presumed to be 
cardiovascular. We have also analyzed recurrent hos-
pitalizations for HF, any cardiovascular, noncardio-
vascular, and all causes. Analyses of other specific 
cardiovascular end points for example, new-onset 
atrial fibrillation were precluded by small numbers.
Statistical Analysis
Baseline characteristics are presented as mean with 
SD or median with interquartile range for continuous 
variables, and frequencies and percentages for cat-
egorical variables. Means were compared using the 
Wilcoxon rank-sum test or Student’s t-test, depending 
on the distribution of the data and proportions using 
the chi-square test. All analyses were performed on 
an intention-to-treat basis. Unadjusted event rates 
are reported per 100 patient-years of follow-up ac-
cording to COPD status. Cumulative event rates were 
estimated using the Kaplan–Meier method and were 
compared using log-rank test. A 2-tailed P-value of 
<0.05 was considered statistically significant.
The prognostic significance of COPD was evaluated 
for the predefined outcomes. The estimated hazard 
ratios (HRs) were adjusted for all the important predic-
tors of mortality and morbidity using Cox proportional 
hazards models. Models were adjusted for region, 
treatment, age, sex, race, systolic blood pressure, 
heart rate, body mass index, serum creatinine, clinical 
features of heart failure (LVEF, NT-proBNP [log]), New 
York Heart Association class, hypertension, diabetes 
mellitus, atrial fibrillation, hospitalization for HF, myo-
cardial infarction, stroke, and duration of HF.
Recurrent hospitalizations (for HF, cardiovascu-
lar, noncardiovascular, and all causes) were analyzed 
using a negative binomial regression model.18 Both 
crude incidence rate ratios (IRRs) and IRRs adjusted 
for the variables mentioned previously are reported. 
All analyses were conducted using STATA version 16 




COPD was present in 1080 of the 8399 enrolled pa-
tients (12.9%), with most patients having been diag-
nosed with COPD for over a year (879/1080). Given 
the large sample size, many differences were statisti-
cally significant but not necessarily clinically signifi-
cant. However, compared with those without COPD, 
patients with COPD were older, more often male, 
White, and had a higher body mass index (Table 1). 
They also had more cardiovascular and noncar-
diovascular comorbidity: atrial fibrillation (44.8% in 
patients with COPD versus 35.6% in those without 
COPD), myocardial infarction (48.1% versus 42.5%), 
diabetes mellitus (39.2% versus 33.8%), and hy-
pertension (80.2% versus 69.3%) (all comparisons 
P<0.001). Current smoking (28.2% versus 12.3%) 
was more common in patients with COPD than in 
those without (both P<0.001).
HF Characteristics
Patients with COPD had worse functional class (New 
York Heart Association III, 35.9% versus 22.3%) and a 
more frequent history of HF hospitalization (70.3% ver-
sus 61.7%; both P<0.001). They displayed more signs of 
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Table 1. Baseline Characteristics of Patients With and Without COPD
No COPD n=7319 COPD n=1080 P Value
Age, y 63.3±11.6 67.4±9.5 <0.001
Female sex, n (%) 1680 (23.0) 152 (14.1) <0.001
Race, n (%) <0.001
White 4655 (63.6) 889 (82.3)
Black 385 (5.3) 43 (4.0)
Asian 1421 (19.4) 88 (8.1)
Other* 858 (11.7) 60 (5.6)
Region, n (%) <0.001
North America 461 (6.3) 141 (13.1)
Latin America 1343 (18.3) 90 (8.3)
Western Europe 1742 (23.8) 309 (28.6)
Central Europe 2374 (32.4) 452 (41.9)
Asia/Pacific and other 1399 (19.1) 88 (8.1)
Date of COPD diagnosis N/A
0–3 mo N/A 58 (5.4)
3–6 mo N/A 61 (5.6)
6–12 mo N/A 82 (7.6)
1–2 y N/A 142 (13.1)
2–5 y N/A 261 (24.2)
>5 y N/A 476 (44.1)
Physiological measures
Systolic BP, mm Hg 121.2±15.4 122.8±14.8 <0.001
Heart rate, bpm 72.2±11.9 73.3±12.4 0.008
Body mass index, kg/m2 28.1±5.4 28.7±6.0 0.001
Laboratory investigations
Hemoglobin, g/L 139.2±15.9 140.6±16.6 0.007
White blood cells, 109/L 6.9±2.0 7.3±2.0 <0.001
Neutrophil count, 109/L 4.3±1.5 4.7±1.7 <0.001
Lymphocyte count,109/L 1.9±0.9 1.9±0.7 0.540
Neutrophil/lymphocyte ratio (%) 2.6±1.6 2.9±1.6 <0.001
Creatinine, μmol/L 98.7±26.1 103.5±27.1 <0.001
Sodium, mmol/L 141.4±3.0 141.8±3.1 <0.001
Potassium, mmol/L 4.5±0.5 4.5±0.5 0.043
Current smoking, n (%) 903 (12.3) 305 (28.2) <0.001
Medical history, n (%)
Hypertension 5074 (69.3) 866 (80.2) <0.001
Atrial fibrillation 2607 (35.6) 484 (44.8) <0.001
Myocardial infarction 3114 (42.5) 520 (48.1) <0.001
Prior CABG 1111 (15.2) 192 (17.8) 0.028
Prior PCI 1521 (20.8) 280 (25.9) <0.001
Prior stable angina 1484 (20.3) 310 (28.7) <0.001
Prior unstable angina 812 (11.1) 158 (14.6) <0.001
Diabetes mellitus 2473 (33.8) 423 (39.2) <0.001
Stroke 620 (8.5) 105 (9.7) 0.170
Cardiovascular treatments at randomization, n (%)
Other antiplatelet 335 (4.6) 52 (4.8) 0.730
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(26.5% versus 20.0%) and rales (11.2 versus 7.4%) than 
participants without COPD (all P<0.001). Patients with 
COPD also had more evidence of coronary heart dis-
ease than patients without COPD (Table 1). They also 
had a lower (worse) Kansas City Cardiomyopathy 
Questionnaire–Clinical Summary Score (KCCQ-CSS; 
73.4 versus 81.2; P<0.001) and higher median NT-
proBNP level (1741 pg/mL versus 1591 pg/mL; P=0.01) 
(Table 2). Left bundle-branch block, was more preva-
lent in patients with COPD than in participants without 
COPD (22.2% versus 19.7% P=0.05, respectively).
Standard Laboratory Measures and 
Cardiovascular Biomarkers
Patients with COPD had a higher serum creatinine 
(103.5±27.1 μmol/L versus 98.7±26.1 μmol/L), white blood 
cell count (7.3±2.0×109/L versus 6.9±2.0×109/L), neu-
trophil count (4.7±1.7×109/L versus 4.3±1.5×109/L), and 
neutrophil/lymphocyte ratio (2.9±1.6% versus 2.6±1.6%; 
P<0.001 for all comparisons). Levels of high-sensitivity 
troponin T, kidney injury molecule-1 and growth differenti-
ating factor 15 were all significantly higher in patients with 
COPD compared with those without COPD (Table 2).
Baseline Cardiovascular Treatment
Medical therapy was similar in patients with and without 
COPD, with 3 exceptions (Table 2). Beta-blockers were 
prescribed less often to patients with COPD compared 
with those without (86.5% versus 94.0%; P<0.001). 
Conversely, use of diuretics and anticoagulants was more 
common in patients with COPD (84.6% versus 79.6%; 
P<0.001; and 35.6% versus 31.4%; P=0.01, respec-
tively). Influenza vaccination rate was low overall but more 
frequent in patients with COPD compared with those 
without COPD (27.8% versus 20.1%; P<0.001; Table 2). 
Patients with COPD were also more frequently enrolled 
in structured disease management program, n (%) (19.7% 
versus 14.6%; P<0.001; Table 2).
Baseline Respiratory Treatment
Overall, 23% of patients with COPD received 1 res-
piratory medication, 15% received 2, and 8% received 
3 drugs. The most commonly used treatments were 
a muscarinic antagonist (24%), a beta-2 adrenoceptor 
agonist (16%), a corticosteroid (11%), and a theophyl-
line (8%) and other agents, including combination 
products (16%).
Outcomes: COPD Versus No COPD
Time-to-First-Event Analyses
COPD was associated with significantly higher risk of 
the primary and all secondary end points: unadjusted 
HR for the primary end point, 1.33 (95% CI, 1.18–1.50); 
cardiovascular death, 1.29 (95% CI, 1.10–1.51); HF 
hospitalization, 1.48 (95% CI, 1.27–1.72); and all-cause 
death, 1.33 (95% CI, 1.16–1.53). After adjustment, the 
risk of the primary end point and HF hospitalization 
remained significantly higher in patients with COPD 
(18% and 32% higher, respectively), while the asso-
ciated risk of cardiovascular and total mortality was 
attenuated and no longer significant (Table 3).
Cause of Hospitalization and Death
COPD was associated with a significantly higher risk 
of cardiovascular and noncardiovascular hospitaliza-
tion: unadjusted HR, 1.29 (95% CI, 1.16–1.44) and 
1.63 (95% CI, 1.45–1.84), respectively. After adjust-
ment for other predictive variables, the risk of car-
diovascular and noncardiovascular hospitalization 
remained significantly higher in patients with COPD 
(17% and 45% higher, respectively, for cardiovascu-
lar and noncardiovascular hospitalization). The risk of 
death caused by worsening HF and sudden death 
was not statistically different between patients with 
and without COPD. However, the risk of noncardio-
vascular death was higher in patients with COPD: un-
adjusted HR, 1.51 (95% CI, 1.12–2.03); adjusted HR, 
1.27 (95% CI, 0.94–1.71; Table 3).
Total HF Hospitalizations
During a median follow-up of 27 months, 216 of 1080 
people (20.0%) with COPD were admitted to the hos-
pital for HF (and experienced a total of 377 admis-
sions). Among the 7319 patients without COPD, 979 
(13.4%) were admitted to the hospital for HF (and ex-
perienced a total of 1553 admissions). The adjusted 
IRR for all HF hospitalizations was 1.35 (95% CI, 1.12–
1.63; Table 4).
No COPD n=7319 COPD n=1080 P Value
Anticoagulants 2301 (31.4) 384 (35.6) 0.007
Statins 4085 (55.8) 638 (59.1) 0.044
Calcium channel blocker 719 (9.8) 115 (10.6) 0.400
Values are mean±SD, n (%), or median (interquartile range), for continuous measures and number (%) for categorical measures. BP indicates blood pressure; 
CABG, coronary artery bypass graft; and PCI, percutaneous coronary intervention.
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Table 2. HF Characteristics of Patients With and Without COPD
No COPD n=7319 COPD n=1080 P Value
Ejection fraction (%) 29.4±6.2 29.9±6.2 0.018
Previous HF hospitalization 4515 (61.7) 759 (70.3) <0.001
NYHA class, n (%) <0.001
I 353 (4.8) 36 (3.3)
II 5273 (72.1) 646 (60.0)
III 1631 (22.3) 387 (35.9)
IV 52 (0.7) 8 (0.7)
KCCQ-CSS 81.2 (64.6–92.7) 73.4 (56.1–87.5) <0.001
Etiology of HF, n (%) <0.001
Ischemic, n (%) 4322 (59.1) 714 (66.1)
Nonischemic, n (%) 2997 (40.9) 366 (33.9)
Signs and symptoms, n (%)
Dyspnea at rest 251 (3.4) 58 (5.4) 0.002
Dyspnea on effort 6243 (85.5) 964 (89.5) <0.001
Orthopnea 509 (7.0) 99 (9.2) 0.009
PND 325 (4.4) 74 (6.9) <0.001
Jugular venous distention 713 (9.8) 105 (9.7) 0.99
Peripheral edema 1463 (20.0) 285 (26.5) <0.001
Third heart sound 707 (9.7) 89 (8.3) 0.14
Rales <0.001
Basilar only 525 (7.2) 112 (10.4)
Greater than third of lung field 17 (0.2) 9 (0.8)
ECG
LBBB 1416 (19.7) 237 (22.2) 0.053
RBBB 536 (7.3) 91 (8.4) 0.200
QRS duration 117.0±35.8 119.9±35.6 0.012
Left ventricular hypertrophy 1319 (18.0) 174 (16.1) 0.130
Biomarkers
NT-proBNP, pg/mL 1591 (882–3171) 1741 (949–3503) 0.011
NT-proBNP, pg/mL with ECG atrial fibrillation/
flutter
1995 (1177–3823) 1995 (1123–4003) 0.920
NT-proBNP, pg/mL without ECG atrial fibrillation/
flutter
1468 (817–2965) 1670 (851–3368) 0.011
Galectin-3, ng/mL 17 (13.8–21.1) 16.9 (14.4–20.9) 0.510
hsTropT, ng/L 16.0 (10.0–25.0) 19.0 (13.0–28.0) <0.001
KIM-1, pg/mL 127.0 (85.4–191.0) 143.5 (96.8–209.0) <0.001
MMP-2, ng/mL 134.1 (115.4–155.8) 136.8 (119.7–162.0) 0.110
MMP-9, ng/mL 630.6 (387.5–1269.8) 668.9 (370.4–1238.5) 0.650
ST2, ng/mL 32.0 (25.5–41.4) 33.7 (25.9–42.0) 0.150
TIMP-1, ng/mL 122.6 (104.2–149.6) 130.9 (10.5.7–156.6) 0.053
GDF-15, ng/L 1613 (1142–2335) 1913 (1365–2721) <0.001
Treatment at randomization, n (%)
Diuretic 5824 (79.6) 914 (84.6) <0.001
Digitalis 2216 (30.3) 323 (29.9) 0.800
Beta-blocker 6877 (94.0) 934 (86.5) <0.001
MRA 4086 (55.8) 585 (54.2) 0.310
ICD 1039 (14.2) 204 (18.9) <0.001
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Among patients with COPD, 132 (12.2%) had 1 HF 
hospitalization, 54 (5.0%) had 2 hospitalizations (total 
108 admissions), and 30 (2.8%) had 3 or more hospi-
talizations (total 137 admissions). Among those with-
out COPD, 653 (8.9%) had 1 HF hospitalization, 199 
(2.7%) had 2 hospitalizations (total 398 admissions), 
and 127 (1.7%) had 3 or more hospitalizations (total 
502 admissions). A full breakdown of repeat HF admis-
sions is given in Table S1, with the distribution shown 
in Figure S1.
Analyses of Total Cardiovascular and Total 
Hospitalizations
During a median follow-up of 27 months, there were 
1523 total hospitalizations for any cause in partici-
pants with COPD and a total of 6094 hospitalizations 
for any cause in patients without COPD (Table  4). 
There were 632 (41.5%) noncardiovascular hospitali-
zations in participants with COPD and 2110 (34.6%) 
in those without COPD. The adjusted IRR for car-
diovascular hospitalization in patients with COPD, 
compared with those without, was 1.30 (95% CI, 
1.14–1.48). The adjusted IRR for noncardiovascular 
hospitalization for patients with COPD, compared 
with those without, was 1.67 (95% CI, 1.44–1.92) and 
for all-cause hospitalization the IRR was 1.43 (95% 
CI, 1.29–1.59; Table 4).
Kansas City Cardiomyopathy Questionnaire–
Clinical Summary Score
On average, the KCCQ-CSS decreased (deterio-
rated) between baseline and 8 months. The mean de-
crease was significantly larger in patients with COPD 
(−6.26±0.26 points) than in those without COPD 
(−3.43±0.25;, P<0.001). A significantly greater pro-
portion of patients reported a clinically meaningful 
deterioration (ie, ≥5-point decrease) in KCCQ–Total 
Symptom Score in the COPD group (32.6%) than in 
the no-COPD group (28.1%; unadjusted odds ratio, 
1.16; 95% CI, 1.01–1.34); fewer COPD patients had a 
clinically meaningful increase (improvement) in KCCQ-
CSS (25.0 versus 27.0%; unadjusted odds ratio, 0.68; 
95% CI, 0.58–0.80; Table 3).
Effect of Sacubitril/Valsartan Compared 
With Enalapril
Although the benefit of sacubitril/valsartan com-
pared with enalapril appeared somewhat attenu-
ated, especially for fatal outcomes, formal statistical 
testing did not show an interaction between COPD 
status and effect of randomized therapy on hospitali-
zation or mortality (Table 5). There was no interaction 
between COPD status and effect of study treatment 
on KCCQ-CSS (Table  5) or mean NT-proBNP at 
8 months.
DISCUSSION
This analysis has several key findings. Patients with 
COPD had notably worse symptoms and quality of 
life despite an overall similar LVEF. Inequalities in 
treatment of HF were apparent only for beta-block-
ers, and less notable than most previous reports.19–23 
Patients with COPD had a higher risk of HF hospitali-
zation and the primary end point but not cardiovas-
cular or all-cause mortality, in contrast with previous 
studies. Additionally, patients with COPD had a 
greater risk of noncardiovascular hospitalization and, 
as a result, all-cause hospitalization. Finally, the ben-
efit of sacubitril/valsartan compared with enalapril 
was consistent across all end points in patients with 
and without COPD.
The prevalence of COPD in PARADIGM-HF was 
consistent with other HF clinical trials,21,22,24,25 and 
lower than in epidemiological studies and regis-
tries.2 Patients with COPD had a greater burden of 
cardiovascular and noncardiovascular comorbidities 
as previously reported.21,26,27 Of interest, both renal 
impairment and hyperkalemia were more common 
in COPD, despite the potassium-lowering action of 
No COPD n=7319 COPD n=1080 P Value
Immunization and lifestyle management
Influenza vaccination in past 12 mo, n (%) 1469 (20.1) 300 (27.8) <0.001
Prescribed exercise regime, n (%) 1258 (17.2) 206 (19.1) 0.130
Enrolled in structured disease management 
program, n (%)
1071 (14.6) 213 (19.7) <0.001
Values are mean±SD, n (%), or median (interquartile range), for continuous measures and number (%) for categorical measures.
CRT indicates cardiac resynchronization therapy (including CRT-pacemaker and CRT-defibrillator); GDF-15, growth differentiating factor 15; HF, heart 
failure; hsTropT, high-sensitivity troponin T; ICD, implantable cardiac defibrillator (including CRT-D); KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire–
Clinical Summary Score; KIM-1, Kidney injury molecule-1; LBBB, left bundle-branch block; MMP, matrix metalloproteinase; MRA, mineralocorticoid receptor 
antagonist; NT pro-BNP, N-terminal pro hormone B-type natriuretic peptide; NYHA, New York Heart Association; PND, paroxysmal nocturnal dyspnea; RBBB, 
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Table 3. Clinical Outcomes in Patients With and Without COPD
Without COPD n=7319 With COPD n=1080 P Value
Primary outcome
Event number 1711 320
Event rate per 100 patient-years 11.33 (10.81–11.88) 15.16 (13.58–16.91)
Unadjusted HR 1.0 (ref) 1.33 (1.18–1.50) <0.001
Adjusted HR 1.0 (ref) 1.18 (1.05–1.34) 0.007
Heart failure hospitalisation
Event number 979 216
Event rate per 100 patient-years 6.48 (6.09–6.90) 10.23 (8.95–11.69)
Unadjusted HR 1.0 (ref) 1.48 (1.27–1.72) <0.001
Adjusted HR 1.0 (ref) 1.32 (1.13–1.54) <0.001
Cardiovascular hospitalisation
Event number 2145 409
Event rate per 100 patient-years 15.75 (15.10–16.43) 22.25 (20.20–24.52)
Unadjusted HR 1.0 (ref) 1.29 (1.16–1.44) <0.001
Adjusted HR 1.0 (ref) 1.17 (1.05–1.31) 0.004
Non-CV hospitalisation
Event number 1427 337
Event rate per 100 patient-years 9.87 (9.37–10.40) 17.64 (15.86–19.63)
Unadjusted HR 1.0 (ref) 1.63 (1.45–1.84) <0.001
Adjusted HR 1.0 (ref) 1.45 (1.29–1.64) <0.001
All cause hospitalisation
Event number 6094 1523
Event rate per 100 patient-years 37.66 (36.72–38.61) 64.55 (61.39–67.88)
Unadjusted HR 1.0 (ref) 1.57 (1.48–1.66) <0.001
Adjusted HR 1.0 (ref) 1.40 (1.32–1.49) <0.001
Cardiovascular death
Event number 1065 186
Event rate per 100 patient-years 6.58 (6.20–6.99) 7.88 (6.83–9.10)
Unadjusted HR 1.0 (ref) 1.29 (1.10–1.51) 0.002
Adjusted HR 1.0 (ref) 1.10 (0.94–1.30) 0.227
Death due to worsening HF
Event number 282 49
Event rate per 100 patient-years 1.74 (1.55–1.96) 2.08 (1.57–2.75)
Unadjusted HR 1.0 (ref) 1.24 (0.91–1.69) 0.174
Adjusted HR 1.0 (ref) 0.98 (0.72–1.35) 0.923
Sudden death
Event number 486 75
Event rate per 100 patient-years 3.00 (2.75–3.28) 3.18 (2.54–3.99)
Unadjusted HR 1.0 (ref) 1.19 (0.93–1.52) 0.165
Adjusted HR 1.0 (ref) 1.10 (0.85–1.41) 0.476
Non-cardiovascular death
Event number 240 55
Event rate per 100 patient-years 1.48 (1.31–1.68) 2.33 (1.79–3.04)
Unadjusted HR 1.0 (ref) 1.51 (1.12–2.03) 0.007
Adjusted HR 1.0 (ref) 1.27 (0.94–1.71) 0.127
All cause death
Event number 1305 241
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beta-agonist bronchodilators.28 Also corroborating 
prior studies, patients with COPD had similar LVEF 
but worse New York Heart Association functional 
status compared with those without.20,26,29,30 We 
explored HF status further, finding higher median 
NT-proBNP in those with COPD. A recent system-
atic review of natriuretic peptides in COPD revealed 
mild elevation in stable disease and more significant 
elevation during acute exacerbations, the causes of 
which may include hypoxia, pulmonary hypertension, 
right ventricular dysfunction, and other comorbidities 
including renal dysfunction.31 Indeed, markers of 
renal function (kidney injury molecule-1 and creati-
nine) were both worse in patients with COPD, and di-
uretic usage was greater. High-sensitivity troponin T 
was also higher, and the reasons for this are likely to 
overlap with those contributing to higher NT-proBNP, 
as well as potentially reflecting the higher prevalence 
of ischemic heart disease in that group. Markers of 
systemic inflammation, including growth differentiat-
ing factor-15 and total white cell count were higher in 
patients with COPD, as was the ratio of neutrophil to 
lymphocyte count. There has been a growing interest 
in the latter as a marker of systemic inflammation and 
its correlation with poorer outcomes in a variety of 
conditions, including HF. COPD was not associated 
with differences in biomarkers of pro-fibrosis (solu-
ble suppression of tumorigenicity 2, tissue inhibitor 
metalloproteinase-1 and galectin 3) nor of collagen 
degradation (matrix metalloproteinase-2 and -9).
Few studies have examined the impact of COPD on 
quality of life. The KCCQ-CSS in HF-ACTION (Heart 
Failure: A Controlled Trial Investigating Outcomes of 
Exercise Training) was worse in patients with COPD 
(61 versus 69 points).29 We found that patients with 
COPD had a markedly lower KCCQ-CSS at baseline 
(73 versus 81, P<0.001) and at 8  months were less 
likely to improve and more likely to experience a clini-
cally important deterioration in KCCQ-CSS, compared 
with patients without COPD. It is possible that even 
with effective HF treatment, progression of COPD may 
lead to worsening of symptoms and quality of life.
Patients with HF and concurrent COPD have histor-
ically been undertreated across the spectrum of care, 
including all neurohormonal antagonists and device 
therapy. However, in PARADIGM-HF, the use of evi-
dence-based therapy was greater than in prior studies 
examining patients with COPD. Not only were base-
line angiotensin-converting enzyme inhibitor, angio-
tensin receptor blocker, and aldosterone antagonist 
levels similar irrespective of COPD status, but those 
with COPD had significantly more devices, particularly 
implantable cardiac defibrillators. The only exception 
was beta-blockade (86% versus 94%). Nevertheless, 
overall beta-blocker uptake has improved compared 
with prior studies, and the treatment gap, albeit per-
sistent, is narrowing.19–23 Further knowledge transla-
tion work is needed, as cardioselective beta-blockers 
are safe and well tolerated in COPD,28,32associated 
with reduced mortality and risk of both HF and COPD 
exacerbation,24,33,34 and recommended in international 
guidelines irrespective of pulmonary disease.35
The low uptake of influenza vaccination is a major 
cause for concern. Vaccination was associated with 
reduced all-cause mortality in a previous analysis from 
PARADIGM-HF,36 although a causal relationship can-
not be inferred because of potential confounders, in-
cluding greater access and quality of health care.37 
Without COPD n=7319 With COPD n=1080 P Value
Unadjusted HR 1.0 (ref) 1.33 (1.16–1.53) <0.001
Adjusted HR 1.0 (ref) 1.14 (0.99–1.31) 0.080
KCCQ-clinical symptom score
Mean change in KCCQ CSS (SE) −3.43 (0.25) −6.26 (0.26)
Difference −2.84 (0.69) <0.001
Proportion with increase in score ≥5 at 8 mo (%) 27.0 25.0
Unadjusted OR 0.68 (0.58–0.80) <0.001
Adjusted OR 0.70 (0.59–0.83) <0.001
Proportion with decrease in score ≥5 at 8 mo (%) 28.1 32.6
Unadjusted OR 1.16 (1.01–1.34) 0.039
Adjusted OR 1.15 (0.99–1.33) 0.068
Event rate is number of events per 100 person-years. Plus-minus values are means±SE. Cox proportional hazard models were used for the clinical outcomes, 
and logistic regression was used for KCCQ-Clinical Summary Score. All models adjusted for treatment and region at baseline. OR additionally adjusted for 
KCCQ-CSS at baseline. Model 1: Adjusted for region, treatment, age, sex, race, systolic blood pressure, heart rate, body mass index, serum creatinine, clinical 
features of heart failure (LVEF, NT-proBNP [log]), NYHA class, hypertension, diabetes mellitus, atrial fibrillation, hospitalization for heart failure, myocardial 
infarction, stroke, and duration of heart failure. COPD indicates chronic obstructive pulmonary disease; HF, heart failure; HR, hazard ratio; KCCQ-CSS, Kansas 
City Cardiomyopathy Questionnaire-Clinical Summary Score; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; 
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Nevertheless, influenza vaccination is recommended in 
international guidelines38 and in multiple observational 
studies associated with reduced hospitalizations and 
mortality in HF.37,39,40 The low rate of influenza vaccina-
tion is even more remarkable considering that the Global 
Initiative for Chronic Obstructive Lung Disease recom-
mends influenza vaccine for all patients with COPD.41
Outcomes
Cause of death has rarely been assessed in patients 
with HF and COPD.22,26,42 In those few prior studies 
and in the present analysis, COPD was associated 
with higher unadjusted but not adjusted risk of car-
diovascular death. Although COPD is portrayed as a 
systemic inflammatory disease, this attenuation of risk 
with multivariable adjustment suggests that cluster-
ing of factors such as comorbidities are largely re-
sponsible for adverse outcomes (as opposed to the 
COPD disease state per se). The unadjusted and 
adjusted risk for all-cause mortality followed a similar 
pattern, largely because 81% of deaths were attrib-
uted to cardiovascular causes. Clinical trial data also 
permit more comprehensive adjustment than most 
population-based studies, including for LVEF and NT-
proBNP. A further consideration is that recruitment 
bias may select patients with milder pulmonary dis-
ease. This is not to discount the importance of COPD 
as a comorbidity in HF—unadjusted risk is most im-
portant from a patient perspective. It simply highlights 
the importance of treating patients in totality.
Prior clinical trials and registries have reported a 
19% to 40% higher risk of HF hospitalization associated 
with COPD.22,42–44 Our findings occupy the midpoint 
of this range (32% higher adjusted risk). Many factors 
may contribute. Pulmonary infection is a common 
precipitant of HF decompensation.45 Beta-blockers, 
a key therapy in reducing HF hospitalization, remain 
underprescribed. Patients with COPD also receive 
bronchodilators, which are associated with increased 
risk of HF hospitalization,46 acknowledging that this 
relationship may be confounded.28 Finally, acute ex-
acerbation of COPD may be responsible for some 
hospitalizations but misdiagnosed as worsening HF. 
However, this is less likely in clinical trials with blinded 
end point adjudication, a key strength of our analysis.
Unfortunately, current smoking remained common 
in patients with COPD (28% versus 12% in those with-
out COPD), and this clearly should mandate more in-
tensive efforts to aid cessation.
Limitations
Several limitations must be acknowledged, foremost 
being the investigator-derived diagnosis of COPD. 
This was obtained from hospital records, pulmonary 
function if available, and questioning the patient. No 
prespecified criteria were defined in the investigator 
brochure. Furthermore, investigators were not required 
to document previous smoking history. Misdiagnosis 
is unavoidable and inherent to all clinical trials lacking 
spirometry.21,22,29,42 Recruitment bias will exclude some 
individuals with severe pulmonary disease. However, 
the generalizability of results is reasonable, as severe 
airflow obstruction is also uncommon in the wider pop-
ulation.30 The exclusion of severe COPD and misclassi-
fication of patients with undiagnosed COPD will reduce 
the apparent magnitude of any association. Finally, in 
this analysis, no adjustment was made for multiplicity.
CONCLUSIONS
In conclusion, patients with HF and concurrent COPD 
have greater comorbidity and higher risk of HF and 
noncardiovascular hospitalization but not mortal-
ity. Inequalities in the treatment of patients with 
COPD were apparent only for beta-blockers, and of 
lesser magnitude than previous studies. Low rates of 
Table 4. Analysis of Repeat Hospitalization in Patients With and Without COPD
Total Events Events Per 100 Person-years No COPD vs COPD

































COPD indicates chronic obstructive pulmonary disease; HF, heart failure; IRR, incident rate ratio; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal 
pro-B-type natriuretic peptide; NYHA, New York Hospital Association. Recurrent hospitalizations were analyzed using a negative binomial regression model, 
which was offset for time. Adjusted for region, treatment, age, sex, race, systolic blood pressure, heart rate, body mass index, serum creatinine, clinical features 
of heart failure (LVEF, NT-proBNP [log]), NYHA class, hypertension, diabetes mellitus, atrial fibrillation, hospitalization for heart failure, myocardial infarction, 
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Table 5. Clinical Outcomes According to Randomized Treatment in Patients With and Without COPD
Without COPD With COPD











Event number 953 758 164 156 0.171
Event rate per 100 
patient-years
12.79 (12.00–13.63) 9.91 (9.23–10.64) 15.77 (13.53–18.38) 14.56 (12.45–17.04)
Unadjusted HR 0.78 (0.71–0.85) 0.92 (0.74–1.15)
HF Hospitalisation
Event number 545 434 113 103 0.430
Event rate per 100 
patient-years
7.31 (6.72–7.95) 5.67 (5.16–6.23) 10.86 (9.03–13.06) 9.62 (7.93–11.66)
Unadjusted HR 0.78 (0.69–0.88) 0.88 (0.67–1.15)
CV hospitalisation
Event number 1146 999 198 211 0.055
Event rate per 100 
patient-years
17.10 (16.14–18.12) 14.44 (13.57–15.37) 21.69 (18.87–24.93) 22.81 (19.93–26.10)
Unadjusted HR 0.85 (0.78–0.92) 1.05 (0.86–1.27)
Non CV hospitalisation
Event number 767 660 164 173 0.098
Event rate per 100 
patient-years
10.74 (10.01–11.53) 9.03 (8.37–9.74) 17.29 (14.84–20.15) 17.99 (15.50–20.88)
Unadjusted HR 0.84 (0.76–0.93) 1.02 (0.82–1.26)
CV death
Event number 598 467 95 91 0.241
Event rate per 100 
patient-years
7.41 (6.84–8.03) 5.75 (5.25–6.30) 8.13 (6.65–9.95) 7.64 (6.22–9.38)
Unadjusted HR 0.78 (0.69–0.88) 0.94 (0.71–1.26)
Non CV death
Event number 111 129 31 24 0.168
Event rate per 100 
patient-years
1.38 (1.14–1.66) 1.59 (1.34–1.89) 2.65 (1.87–3.77) 2.01 (1.35–3.01)
Unadjusted HR 1.15 (0.89–1.48) 0.76 (0.44–1.29)
All cause death
Event number 709 596 126 115
Event rate per 100 
patient-years
8.79 (8.17–9.46) 7.34 (6.78–7.96) 10.79 (9.06–12.85) 9.65 (8.04–11.59) 0.638
Unadjusted HR 0.84 (0.75–0.93) 0.90 (0.70–1.16)
KCCQ CSS
Mean change in KCCQ at 8 mo 
(SE)
−4.50 (0.35) −2.74 (0.35) −5.63 (0.91) −4.47 (0.89)
Between treatment difference 1.76 (0.5) 1.16 (1.27) 0.449
Proportion with increase in 
score ≥5 at 8 mo, n (%)
978 (26.6) 997 (27.4) 135 (25.5) 135 (24.5) 0.377
Proportion with decrease in 
score ≥5 at 8 mo, n (%)
1104 (30.0) 951 (26.1) 179 (33.8) 173 (31.5) 0.580
NT–proBNP
Mean change in NT-proBNP at 
8 mo (pg/ml)
−536±2888 −990±2697 −593±2235 1058±2454 0.971
Between treatment difference 454 (171–736) 466 (−53–985)
All models adjusted for treatment and region at baseline. Event rate is number of events per 100 person-years. Plus-minus values are means±SE. Cox 
proportional hazard models were used for the clinical outcomes.
CV indicates cardiovascular; HF, heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; NT-proBNP, N-terminal pro hormone B-type natriuretic 
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influenza vaccination and high prevalence of continu-
ing smoking in patients with HF and COPD represent 
ongoing targets for public health initiatives and quality 
improvement.
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Table S1. Number of patients admitted to hospital one or more times with heart failure 








(%) of patients 
without COPD 
admitted  








Total Number (%) 
of patients with 
COPD admitted  
 
Total number of 
admissions for 
patients with 
COPD, n  
1  653 (8.92)  653  132 (12.22)  132  
2  199 (2.72)  398  54 (5.00)  108  
3  73 (1.00)  219  13 (1.20)  39  
4  27 (0.37)  108  4 (0.37)  16  
5  13 (0.18)  65  8 (0.74)  40  
6  4 (0.05)  24  1 (0.09)  6  
7  6 (0.08)  42  1 (0.09)  7  
8  1 (0.01)  8  0 (0.00)  0  
9  2 (0.03)   18  2 (0.19)  18  
11  0 (0.00)  0  1 (0.09)  11  
18  1 (0.01)  18  0 (0.00)  0  
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